Veracyte Inc. (VCYT)
Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Veracyte, Inc. (VCYT) could be a good stock pick from a technical perspective. VCYT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue?
Veracyte (VCYT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up
Veracyte's (VCYT) second-quarter 2024 performance reflects the strength of its testing business.
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
On Tuesday, Veracyte, Inc VCYT reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Shayla Gorman – Senior Director, Investor Relations Marc Stapley – Chief Executive Officer Rebecca Chambers – Chief Financial Officer Conference Call Participants Mason Carrico – Stephens, Inc. Yuko Oku – Morgan Stanley Maggie Boeye – William Blair Joseph Conway – Needham & Company Prashant Kota – Goldman Sachs Thomas DeBourcy – Nephron Research Operator Good day and thank you for standing by. Welcome to the Veracyte Second Quarter 2024 Financial Results Call.
Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.12 per share a year ago.
Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?
Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns
Invest in companies like Veracyte (VCYT), Steelcase (SCS) and Applied Industrial Technologies (AIT), as they boast higher efficiency levels.
Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?
The mean of analysts' price targets for Veracyte (VCYT) points to a 37.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
